NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Allstate Corporation (NYSE:ALL), Seattle Genetics, Inc. (NASDAQ:SGEN), Intra-Cellular Therapies Inc. (NASDAQ:ITCI), AMN Healthcare Services Inc (NYSE:AMN), AVX Corporation (NYSE:AVX), and DURECT Corporation (NASDAQ:DRRX), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

ALL DOWNLOAD: http://Fundamental-Markets.com/register/?so=ALL
SGEN DOWNLOAD: http://Fundamental-Markets.com/register/?so=SGEN
ITCI DOWNLOAD: http://Fundamental-Markets.com/register/?so=ITCI
AMN DOWNLOAD: http://Fundamental-Markets.com/register/?so=AMN
AVX DOWNLOAD: http://Fundamental-Markets.com/register/?so=AVX
DRRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=DRRX

The new research reports from Fundamental Markets, available for free download at the links above, examine The Allstate Corporation (NYSE:ALL), Seattle Genetics, Inc. (NASDAQ:SGEN), Intra-Cellular Therapies Inc. (NASDAQ:ITCI), AMN Healthcare Services Inc (NYSE:AMN), AVX Corporation (NYSE:AVX), and DURECT Corporation (NASDAQ:DRRX) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

For the three months ended December 31st, 2018 vs December 31st, 2017, The Allstate reported revenue of $9,481.00MM vs $10,062.00MM (down 5.77%) and analysts estimated basic earnings per share -$0.85 vs $3.40. For the twelve months ended December 31st, 2018 vs December 31st, 2017, The Allstate reported revenue of $39,815.00MM vs $39,407.00MM (up 1.04%) and analysts estimated basic earnings per share $6.05 vs $8.49 (down 28.74%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $2.96. The estimated EPS forecast for the next fiscal year is $9.90 and is expected to report on February 4th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, Seattle Genetics reported revenue of $174.51MM vs $129.61MM (up 34.65%) and analysts estimated basic earnings per share -$0.74 vs -$0.42. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Seattle Genetics reported revenue of $654.70MM vs $482.25MM (up 35.76%) and analysts estimated basic earnings per share -$1.41 vs -$0.88. Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.61. The estimated EPS forecast for the next fiscal year is $0.10 and is expected to report on February 6th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, AMN Healthcare Services reported revenue of $528.64MM vs $509.08MM (up 3.84%) and basic earnings per share $0.76 vs $0.86 (down 11.63%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, AMN Healthcare Services reported revenue of $2,136.07MM vs $1,988.45MM (up 7.42%) and analysts estimated basic earnings per share $2.99 vs $2.77 (up 7.94%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.81. The estimated EPS forecast for the next fiscal year is $3.39 and is expected to report on February 13th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, AVX reported revenue of $442.40MM vs $431.80MM (up 2.45%) and analysts estimated basic earnings per share $0.44 vs -$0.55. For the twelve months ended March 31st, 2018 vs March 31st, 2017, AVX reported revenue of $1,562.47MM vs $1,312.66MM (up 19.03%) and analysts estimated basic earnings per share $0.03 vs $0.75 (down 96.00%). Analysts expect earnings to be released on April 22nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.19. The estimated EPS forecast for the next fiscal year is $1.50 and is expected to report on April 22nd, 2019.

For the three months ended December 31st, 2018 vs December 31st, 2017, DURECT reported revenue of $3.63MM vs $19.54MM (down 81.44%) and analysts estimated basic earnings per share -$0.05 vs $0.06. For the twelve months ended December 31st, 2018 vs December 31st, 2017, DURECT reported revenue of $18.56MM vs $49.17MM (down 62.25%) and analysts estimated basic earnings per share -$0.16 vs -$0.03. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.05. The estimated EPS forecast for the next fiscal year is -$0.19 and is expected to report on March 5th, 2020.

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.